Jenex re­ceives TherOZap re­sults for Zika test­ing

The Jenex Corp. has re­ceived ini­tial re­sults on Zika virus test­ing with TherOZap. Re­sults have shown that in­fected cells treated with TherOZap had “lower cy­to­pathic ef­fect” com­pared with in­fected cells that did not re­ceive treat­ment.

Stockwatch Daily - - FRONT PAGE - Mr. Rob Fia re­ports

THE JENEX Corp. has re­ceived promis­ing ini­tial re­sults on the Zika virus test­ing with TherOZap.

D r . Alyson Kelvin at UHN (Univer­sity Health Net­work) re­ported the fol­low­ing: “To eval­u­ate the ef­fec­tive­ness of the Jenex TherOZap de­vice against the in­fec­tiv­ity of Zika virus, cells were in­fected with a range of Zika virus doses and treated with the Jenex de­vice with heat. In the cells that re­ceived the low­est vi­ral dose, ini­tial re­sults showed in­fected cells that had been treated with the Jenex TherOZap de­vice had a markedly lower cy­to­pathic ef­fect com­pared to in­fected cells that did not re­ceive treat­ment. Th­ese pre­lim­i­nary re­sults need to be con­firmed through re­peated test­ing as well as by mea­sure­ment of virus vi­a­bil­ity. Cy­to­pathic ef­fect is a mea sure of cel lu lar patho­gen­e­sis and cel­lu­lar vi­a­bil­ity in re­la­tion to vi­ral in­fec­tion; re­sults of a vi­ral repli­ca­tion as­say and mea­sure­ments of live vi­ral ac­tiv­ity are pend­ing.”

Rob Fia, chief ex­ec­u­tive of­fi­cer of Jenex, com­mented: “We are pleased with the ini­tial test re­sults on the Zika virus with our patent-pend­ing TherOZap tech­nol­ogy. Jenex is ex­cited about th­ese ini­tial tests re­sults, and we look for­ward to fur­ther data as it be­comes avail­able from Techna In­sti­tute at UHN. Jenex will have more to re­port to over the next sev­eral weeks.”

About The Jenex Corp.

Jenex is a pro­gres­sive med­i­cal de­vice tech­nol­ogy com­pany fo­cused on pro­vid­ing con­sumers with qual­ity med­i­cal de­vices that ad­dress their der­ma­to­log­i­cal needs. The com­pany’s break­through pro­pri­etary tech­nol­ogy de­liv­ers ef­fec­tive, non-in­va­sive and pain-free skin care.

Jenex re­ceived a Class II med­i­cal de­vice sta­tus from the U.S. Food and Drug Ad­min­is­tra­tion for its plat­form tech­nol­ogy that is in­di­cated for the re­lief of the pain, itch and in­flam­ma­tion from over 20,000 dif­fer­ent in­sect stings and bites (in­clud­ing bees, wasps, hor­nets, mosquitoes, black flies and jel­ly­fish).

We seek Safe Har­bor.

Roberto Fia, John R Gam­ble, Joseph Ching-Hiang Heng

(JEN) Shares: 135,043,740

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.